DMRA · Damora Therapeutics, Inc. · Executive Compensation
$21.96
+0.70 (+3.29%)
At close · Oct 27
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$1.36B
Shares
61.74M
Volume · Oct 27
286.1K
Avg daily vol (3M)
520.19K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Hans T. Schambye | M.D., Ph.D. Former President and Chief Executive Officer | $1,299,792 |
| Garrett Winslow | General Counsel | $854,755 |
| Lori Firmani | Chief Financial Officer | $563,211 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Hans T. Schambye | M.D., Ph.D. President and Chief Executive Officer | $1,429,550 |
| Garrett Winslow | General Counsel | $897,368 |
| Jonathan Freve | Former Chief Financial Officer | $819,754 |
| Lori Firmani | Chief Financial Officer | $561,892 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Hans T. Schambye | M.D., Ph.D. President and Chief Executive Officer | $965,115 |
| Bertil Lindmark | M.D., Ph.D. Former Chief Medical Officer | $819,618 |
| Jonathan Freve | Former Chief Financial Officer | $701,329 |
| Garrett Winslow | General Counsel | $554,388 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Hans T. Schambye | M.D., Ph.D. President and Chief Executive Officer | $1,394,817 |
| Jonathan Freve | Chief Financial Officer | $889,113 |
| Bertil Lindmark | M.D., Ph.D. Former Chief Medical Officer | $814,998 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Hans T. Schambye | M.D., Ph.D. President and Chief Executive Officer | $2,947,004 |
| Jonathan Freve | Chief Financial Officer | $1,514,891 |
| Anders Pedersen | Chief Operating Officer | $1,502,051 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Hans T. Schambye | M.D., Ph.D. President and Chief Executive Officer | $3,903,539 |
| Anders Pedersen | Chief Operating Officer | $1,091,173 |
| Bertil Lindmark | M.D., Ph.D.^(^^4)^ Chief Medical Officer | $812,929 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Hans T. Schambye | M.D., Ph.D. President and Chief Executive Officer | $479,000 |
| Anders Pedersen | Chief Operating Officer | $355,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Brian Burkavage | principal financial officer and principal accounting officer | Appointed | 2026-05-04 |
| Mike Landsittel | Board of Directors | Appointed | 2026-03-23 |
| Cameron Turtle | Board of Directors | Appointed | 2026-03-23 |
| Peter Harwin | Chairman of the Board of Directors | Appointed | 2026-03-23 |
| Peter Harwin | chair of the Board | Appointed | 2026-03-23 |
| Cameron Turtle | Class III director | Appointed | 2026-03-23 |
| Carl Goldfischer | director | Resigned | 2026-03-23 |
| Michael Landsittel | Class III director | Appointed | 2026-03-23 |
| Jayson Dallas | director | Resigned | 2026-03-23 |
| Amit Munshi | director | Resigned | 2026-03-23 |
| Jennifer Jarrett | Class II director | Appointed | 2026-03-23 |
| Jennifer Jarrett | President and Chief Executive Officer | Appointed | 2026-03-23 |
| Hans T. Schambye | board | Resigned | 2026-02-10 |
| Sherwin Sattarzadeh | interim principal executive officer | Appointed | 2026-02-10 |
| Sherwin Sattarzadeh | Chief Operating Officer | Appointed | 2026-01-06 |
| Lori Firmani | Chief Financial Officer | Appointed | 2025-11-10 |
| Julianne Bruno | Board | Appointed | 2025-11-10 |
| Chris Cain | Board | Appointed | 2025-11-10 |
| Peter Harwin | Board | Appointed | 2025-11-10 |
| David Shapiro | Board | Resigned | 2025-11-10 |
| Amy Wechsler | Board | Resigned | 2025-11-10 |
| Anne Prener | Board | Resigned | 2025-11-10 |
| Amy Wechsler | Class I director | Appointed | 2024-10-15 |
| Matthew Kronmiller | member of Buyer's senior management team | Appointed | 2024-10-07 |
| Bertil Lindmark, M.D. | Chief Medical Officer | Terminated | 2023-09-26 |
Leadership
- Jennifer Jarrett CEO, Board Member
- Sherwin Sattarzadeh CEO, COO
- Peter Harwin Chairman, Board Member
- Lori Firmani CFO
- Garrett Winslow General Counsel
- Brian Burkavage Chief Accounting Officer
- Amy Wechsler Board Member
- Cameron Turtle Board Member
- Chris Cain Board Member
- Chris Cain, Ph.D. Board Member
- Julianne Bruno Board Member
- Michael Landsittel Board Member
- Mike Landsittel Board Member